刘颖

Cooley advised Fangdd on its $78 million initial public offering of 6,000,000 American depositary shares, each representing 25 class A ordinary shares. The underwriters have a 30-day option to purchase up to 900,000 additional shares. The transaction represents Cooley’s first completed IPO out of its newly launched Hong Kong office. Partner Will Cai led the Cooley team advising Fangdd. Founded in 2011 by former real estate agents Yi Duan and Xi Zeng, Fangdd now trades its securities on the Nasdaq Global Select Market under the symbol “DUO.”

Cooley advised Legend Biotech on its $487.3 million initial public offering of 21,188,750 American Depository Shares (ADSs). Legend Biotech, whose securities now trade on the Nasdaq Global Select Market under the symbol “LEGN”, is global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Partners Div Gupta, Rob Phillips, Will Cai, Michael Yu and Rich Segal led the Cooley team.

Cooley advised GOGOX, an online intracity logistics platform in Asia focused on the transportation of freight and goods in urban areas, on its HK$675 million (US$86 million) initial public offering of 3,120,000 shares (subject to an overallotment option to issue an additional 4,680,000 shares), which now trade on the Hong Kong Stock Exchange. Partners Michael Yu and Will Cai led the Cooley team advising GOGOX, which also included Lisa Yuan, Marcus Chen, Ying Liu, Keke Wu, Jasmine Li, April Wang, Cindy Pan, Shuaiwen Wang, Jieting Zhang and Freeda Li.

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.